BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Zahiri M, Taghavi S, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Theranostic nanobubbles towards smart nanomedicines. J Control Release 2021;339:164-94. [PMID: 34592384 DOI: 10.1016/j.jconrel.2021.09.032] [Reference Citation Analysis]
2 Wang X, Mao M, He Z, Zhang L, Li H, Lin J, He Y, Dai S, Hu W, Liu W. Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci 2019;15:221-8. [PMID: 30662361 DOI: 10.7150/ijbs.28720] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
3 Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211-216. [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 11.7] [Reference Citation Analysis]
4 Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, Yin L, Han Y, Shen H. BMP4 enhances hepatocellular carcinoma proliferation by promoting cell cycle progression via ID2/CDKN1B signaling. Mol Carcinog 2017;56:2279-89. [PMID: 28543546 DOI: 10.1002/mc.22681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
5 Scherber PR, Gäbelein G, Eisele RM, Igna D, Glanemann M. [Early stage liver cancer : Hepatocellular carcinoma]. Chirurg 2018;89:281-8. [PMID: 29075797 DOI: 10.1007/s00104-017-0538-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Chiu CC, Wang JJ, Chen YS, Chen JJ, Tsai TC, Lai CC, Sun DP, Shi HY. Trends and predictors of outcomes after surgery for hepatocellular carcinoma: A nationwide population-based study in Taiwan. Eur J Surg Oncol 2015;41:1170-8. [PMID: 26048295 DOI: 10.1016/j.ejso.2015.04.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1355-65. [PMID: 34805014 DOI: 10.2147/JHC.S339707] [Reference Citation Analysis]
8 Luo CL, Rong Y, Chen H, Zhang WW, Wu L, Wei D, Wei XQ, Mei LJ, Wang FB. A Logistic Regression Model for Noninvasive Prediction of AFP-Negative Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819846632. [PMID: 31106685 DOI: 10.1177/1533033819846632] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
9 Cao X, Cao Z, Ou C, Zhang L, Chen Y, Li Y, Zhu B, Shu H. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients. Clin Res Hepatol Gastroenterol 2021;45:101583. [PMID: 33756265 DOI: 10.1016/j.clinre.2020.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, Mao Y, Cheng YF, Teng GJ, Lau WY. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022;102:106094. [PMID: 35662438 DOI: 10.1016/j.ijsu.2021.106094] [Reference Citation Analysis]
11 Yang JY, Li M, Zhang CL, Liu D. Pharmacological properties of baicalin on liver diseases: a narrative review. Pharmacol Rep 2021;73:1230-9. [PMID: 33595821 DOI: 10.1007/s43440-021-00227-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin. 2014;53:39-45. [PMID: 24777354 DOI: 10.3413/nukmed-0622-13-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
13 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
14 Kim D, Kim J, Kwak CH, Heo NS, Oh SY, Lee H, Lee G, Vilian AE, Han Y, Kim W, Kim G, Kwon S, Huh YS. Rapid and label-free bioanalytical method of alpha fetoprotein detection using LSPR chip. Journal of Crystal Growth 2017;469:131-5. [DOI: 10.1016/j.jcrysgro.2016.09.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Kondo Y, Kimura O, Shimosegawa T. Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol 2015;8:109-15. [PMID: 25855582 DOI: 10.1007/s12328-015-0568-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
16 Bergquist JR, Shah HN, Habermann EB, Hernandez MC, Ivanics T, Kendrick ML, Smoot RL, Nagorney DM, Borad MJ, Mcwilliams RR, Truty MJ. Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). International Journal of Surgery 2018;52:171-9. [DOI: 10.1016/j.ijsu.2018.02.052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
17 Kondo Y, Kimura O, Shimosegawa T. Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. World J Gastroenterol 2015; 21(1): 94-101 [PMID: 25574082 DOI: 10.3748/wjg.v21.i1.94] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
18 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
19 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
20 Vickress J, Lock M, Lo S, Gaede S, Leung A, Cao J, Barnett R, Yartsev S. A multivariable model to predict survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy. Future Oncol 2017;13:19-30. [PMID: 27582002 DOI: 10.2217/fon-2016-0252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9:e107986. [PMID: 25238238 DOI: 10.1371/journal.pone.0107986] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 13.1] [Reference Citation Analysis]
22 Akai H, Yasaka K, Kunimatsu A, Nojima M, Kokudo T, Kokudo N, Hasegawa K, Abe O, Ohtomo K, Kiryu S. Predicting prognosis of resected hepatocellular carcinoma by radiomics analysis with random survival forest. Diagnostic and Interventional Imaging 2018;99:643-51. [DOI: 10.1016/j.diii.2018.05.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
23 Liu Z, Zhang J, Tian Y, Zhang L, Han X, Wang Q, Cheng W. Targeted delivery of reduced graphene oxide nanosheets using multifunctional ultrasound nanobubbles for visualization and enhanced photothermal therapy. Int J Nanomedicine 2018;13:7859-72. [PMID: 30538464 DOI: 10.2147/IJN.S181268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Zhu HT, Liu RB, Liang YY, Hasan AME, Wang HY, Shao Q, Zhang ZC, Wang J, He CY, Wang F, Shao JY. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int. 2017;37:888-896. [PMID: 28061012 DOI: 10.1111/liv.13356] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
25 Bridges JF, Joy SM, Blauvelt BM, Yan W, Marsteller JA. An international comparison of stakeholder motivation to implement liver cancer control. Health Policy Plan 2015;30:645-55. [PMID: 24974105 DOI: 10.1093/heapol/czu044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Borzio M, Sacco R. Nonadherence to guidelines in the management of hepatocellular carcinoma: an Italian or universal phenomenon? Future Oncol. 2013;9:465-467. [PMID: 23560367 DOI: 10.2217/fon.13.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
27 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Huang L, Mo Z, Hu Z, Zhang L, Qin S, Qin X, Li S. Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma. Cancer Cell Int 2020;20:77. [PMID: 32190001 DOI: 10.1186/s12935-020-1161-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
29 Khan R, Zahid S, Wan YJ, Forster J, Karim AB, Nawabi AM, Azhar A, Rahman MA, Ahmed N. Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. Clin Proteomics 2013;10:6. [PMID: 23724895 DOI: 10.1186/1559-0275-10-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
30 Saini S, Pratt DS. Time to update radiological criteria for non-invasive diagnosis of hepatocellular carcinoma. Hepatol Int 2015;9:1-2. [DOI: 10.1007/s12072-014-9584-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
32 Choi J, Kim GA, Han S, Lim YS. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol 2020;115:406-14. [PMID: 31895708 DOI: 10.14309/ajg.0000000000000490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Yu Z, Luo X, Wang C, Ye J, Liu S, Xie L, Wang F, Bao J. Baicalin promoted site-2 protease and not site-1 protease in endoplasmic reticulum stress-induced apoptosis of human hepatocellular carcinoma cells. FEBS Open Bio 2016;6:1093-101. [PMID: 27833850 DOI: 10.1002/2211-5463.12130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
34 Tang A, Cruite I, Sirlin CB. Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol. 2013;7:269-279. [PMID: 23445236 DOI: 10.1586/egh.13.3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
35 Lesurtel M, Perrier A, Bossuyt PM, Langer B, Clavien P. An independent jury-based consensus conference model for the development of recommendations in medico-surgical practice. Surgery 2014;155:390-7. [DOI: 10.1016/j.surg.2013.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
36 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One 2014;9:e99115. [PMID: 24906132 DOI: 10.1371/journal.pone.0099115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
37 Song P, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand J Clin Lab Invest Suppl 2016;245:S70-6. [PMID: 27438343 DOI: 10.1080/00365513.2016.1210328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
38 Ohri N, Kaubisch A, Garg M, Guha C. Targeted Therapy for Hepatocellular Carcinoma. Semin Radiat Oncol 2016;26:338-43. [PMID: 27619254 DOI: 10.1016/j.semradonc.2016.06.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
39 Nguang SH, Wu CK, Liang CM, Tai WC, Yang SC, Ku MK, Yuan LT, Wang JW, Tseng KL, Hung TH, Hsu PI, Wu DC, Chuah SK, Hsu CN. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. Int J Environ Res Public Health 2018;15:E2655. [PMID: 30486324 DOI: 10.3390/ijerph15122655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
40 Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441-447. [PMID: 28081537 DOI: 10.1038/bjc.2016.422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
41 Tang A, Valasek MA, Sirlin CB. Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know. Adv Anat Pathol 2015;22:314-22. [PMID: 26262514 DOI: 10.1097/PAP.0000000000000089] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
42 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
43 Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.Cancer Biomark. 2018;21:603-612. [PMID: 29278878 DOI: 10.3233/CBM-170551] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
44 Yacoub JH, Miller FH. Understanding LI-RADS, Its Relationship to AASLD and OPTN, and the Challenges of Its Adoption. Curr Hepatology Rep 2017;16:72-80. [DOI: 10.1007/s11901-017-0337-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
45 Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Tang W. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr. 2013;2:227-231. [PMID: 24570947 DOI: 10.3978/j.issn.2304-3881.2013.08.11] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
46 Mao M, Wang X, Song Y, Sheng H, Han R, Lin W, Dai S. Novel Prognostic Scores Based on Plasma Prothrombin Time and Fibrinogen Levels in Patients With AFP-Negative Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820915520. [PMID: 32216575 DOI: 10.1177/1073274820915520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Guo X, Ye S. Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma. JCO 2015;33:894-900. [DOI: 10.1200/jco.2013.52.9651] [Cited by in Crossref: 71] [Cited by in F6Publishing: 30] [Article Influence: 10.1] [Reference Citation Analysis]
48 Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol 2017; 9(14): 645-656 [PMID: 28588749 DOI: 10.4254/wjh.v9.i14.645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
49 Ren B, Zou G, Xu F, Huang Y, Xu G, He J, Li Y, Zhu H, Yu P. Serum levels of anti-sperm-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma. Oncol Lett. 2017;14:7608-7614. [PMID: 29344208 DOI: 10.3892/ol.2017.7152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
50 Mochizuki S, Nakayama H, Higaki T, Okubo T, Midorikawa Y, Moriguchi M, Aramaki O, Yamazaki S, Sugitani M, Takayama T. Repeat liver resection for hepatocellular carcinoma complicating primary biliary cirrhosis. Int Surg. 2013;98:424-427. [PMID: 24229035 DOI: 10.9738/intsurg-d-13-00082.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
52 Schoenberg M, Khandoga A, Stintzing S, Trumm C, Schiergens TS, Angele M, Op den Winkel M, Werner J, Muacevic A, Rentsch M. CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC? Cureus 2016;8:e591. [PMID: 27284498 DOI: 10.7759/cureus.591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Cruite I, Tang A, Sirlin CB. Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201:41-55. [PMID: 23789657 DOI: 10.2214/ajr.13.10570] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
54 Mah WC, Lee CG. DNA methylation: potential biomarker in Hepatocellular Carcinoma. Biomark Res. 2014;2:5. [PMID: 24635883 DOI: 10.1186/2050-7771-2-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
55 Tan HL, Goh BKP. Management of recurrent hepatocellular carcinoma after resection. Hepatobiliary Surg Nutr 2020;9:780-3. [PMID: 33299834 DOI: 10.21037/hbsn.2020.03.07] [Reference Citation Analysis]
56 Liu X, Wang Z, Chen Z, Liu L, Ma L, Dong L, Zhang Z, Zhang S, Yang L, Shi J, Fan J, Wang X, Gao Q. Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Oncol Res 2018;26:231-9. [PMID: 28911342 DOI: 10.3727/096504017X15051752095738] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
57 Yoon YM, Kang DY, Kim DY, Seo JW, Lim HJ, Lee HJ, Park SG. Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report. J Med Case Rep 2016;10:140. [PMID: 27246404 DOI: 10.1186/s13256-016-0915-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Becker-assmann J, Fard-aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, von Hahn T, Oldhafer KJ. Diagnostische und prognostische Bedeutung des α-Feto-Proteins beim hepatozellulären Karzinom. Chirurg 2020;91:769-77. [DOI: 10.1007/s00104-020-01118-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
60 Li D, Satomura S. Biomarkers for Hepatocellular Carcinoma (HCC): An Update. Adv Exp Med Biol 2015;867:179-93. [PMID: 26530367 DOI: 10.1007/978-94-017-7215-0_12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
61 Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, Ehman EC, Fowler KJ, Hussain HK, Jha RC, Karam AR, Mamidipalli A, Marks RM, Mitchell DG, Morgan TA, Ohliger MA, Shah A, Vu KN, Sirlin CB; LI-RADS Evidence Working Group. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 2018;286:29-48. [PMID: 29166245 DOI: 10.1148/radiol.2017170554] [Cited by in Crossref: 131] [Cited by in F6Publishing: 128] [Article Influence: 26.2] [Reference Citation Analysis]
62 Fan SS, Liao CS, Cao YD, Xiao PL, Deng T, Luo RC, Duan HX. A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma. Oncol Lett 2017;13:4208-14. [PMID: 28599422 DOI: 10.3892/ol.2017.6024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
63 Li Q, Li H, He C, Jing Z, Liu C, Xie J, Ma W, Deng H. The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. Eur J Med Res 2017;22:48. [PMID: 29162156 DOI: 10.1186/s40001-017-0291-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
64 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
65 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
66 Saito Y, Abiko R, Kishida A, Kuwahara Y, Yamamoto Y, Yamamoto F, Fukumoto M, Ohkubo Y. Loss of EGF-dependent cell proliferation ability on radioresistant cell HepG2-8960-R. Cell Biochem Funct 2015;33:73-9. [PMID: 25663666 DOI: 10.1002/cbf.3090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Kuo ZK, Lin MW, Lu IH, Yao HJ, Wu HC, Wang CC, Lin SH, Wu SY, Tong TS, Cheng YC, Yen JH, Ko CH, Chiou SJ, Pan IH, Tseng HW. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complement Altern Med 2016;16:277. [PMID: 27502492 DOI: 10.1186/s12906-016-1250-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
68 Thaiss WM, Sauter AW, Bongers M, Horger M, Nikolaou K. Clinical applications for dual energy CT versus dynamic contrast enhanced CT in oncology. European Journal of Radiology 2015;84:2368-79. [DOI: 10.1016/j.ejrad.2015.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
69 Jha RC, Mitchell DG, Weinreb JC, Santillan CS, Yeh BM, Francois R, Sirlin CB. LI-RADS Categorization of Benign and Likely Benign Findings in Patients at Risk of Hepatocellular Carcinoma: A Pictorial Atlas. American Journal of Roentgenology 2014;203:W48-69. [DOI: 10.2214/ajr.13.12169] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
70 Yamamoto G, Taura K, Ikai I, Fujikawa T, Nishitai R, Kaihara S, Zaima M, Terajima H, Yoshimura T, Koyama Y, Tanabe K, Nishio T, Okuda Y, Ikeno Y, Yoshino K, Fukuyama K, Seo S, Hatano E, Uemoto S. ALPlat criterion for the resection of hepatocellular carcinoma based on a predictive model of posthepatectomy liver failure. Surgery 2020;167:410-6. [DOI: 10.1016/j.surg.2019.09.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
71 Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, Salleron J, Henrot P. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 2017;12:e0176118. [PMID: 28441447 DOI: 10.1371/journal.pone.0176118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
72 Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol 2020;20:215. [PMID: 32646378 DOI: 10.1186/s12876-020-01365-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Young K, Fidelman N, Yao FY, Hills NK, Kohi MP, Kolli KP, Taylor AG, Kerlan RK Jr. Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma. Liver Transpl 2015;21:454-67. [PMID: 25678220 DOI: 10.1002/lt.24090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]